Novel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented Pump and Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes Mellitus

Size: px
Start display at page:

Download "Novel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented Pump and Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes Mellitus"

Transcription

1 543660DSTXXX / Journal of Diabetes Science and TechnologySrinivasan et al research-article2014 Original Article Novel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented Pump and Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes Mellitus Journal of Diabetes Science and Technology 2014, Vol. 8(5) Diabetes Technology Society Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / dst.sagepub.com Asavari Srinivasan, MS 1, Joon Bok Lee, BS 1,2, Eyal Dassau, PhD 1,2, and Francis J. Doyle III, PhD 1,2 Abstract Background: Maintaining euglycemia for people with type 1 diabetes is highly challenging, and variations in glucose absorption rates with meal composition require meal type specific insulin delivery profiles for optimal blood glucose control. Traditional basal/bolus therapy is not fully optimized for meals of varied fat contents. Thus, regimens for low- and high-fat meals were developed to improve current insulin pump therapy. Method: Simulations of meals with varied fat content demonstrably replicated published data. Subsequently, an insulin profile library with optimized delivery regimens under open and closed loop for various meal compositions was constructed using particle swarm optimization. Results: Calculations showed that the optimal basal bolus insulin profiles for low-fat meals comprise a normal bolus or a short wave. The preferred delivery for high-fat meals is typically biphasic, but can extend to multiple phases depending on meal characteristics. Results also revealed that patients that are highly sensitive to insulin could benefit from biphasic deliveries. Preliminary investigations of the optimal closed-loop regimens also display bi- or multiphasic patterns for high-fat meals. Conclusions: The novel insulin delivery profiles present new waveforms that provide better control of postprandial glucose excursions than existing schemes. Furthermore, the proposed novel regimens are also more or similarly robust to uncertainties in meal parameter estimates, with the closed-loop schemes demonstrating superior performance and robustness. Keywords artificial pancreas, biomedical control, bolus wizard, insulin dosage, insulin pump therapy, particle swarm optimization, type 1 diabetes Type 1 diabetes mellitus (T1DM) is a chronic condition caused by autoimmune destruction of pancreatic β-cells. 1 Without adequate insulin secretion, the body cannot metabolize blood glucose (BG). Since glucose is the main energy source for the body, maintaining euglycemia, or normal BG, is essential to avoid serious complications associated with hypo- and hyperglycemia. 2 In people with T1DM, rapid increases in BG from meals are difficult to control due to the lack of cephalic insulin delivery prior to consumption. Consequently, meal compensation is a main challenge in BG control. T1DM is commonly treated with continuous subcutaneous insulin injections (CSIIs), 3 combined with user calculated insulin boluses prior to meals. Insulin pump therapy, a CSII system, performs automatic calculations of insulin dose required to cover ingested carbohydrates (CHO). 4 Automated closed-loop insulin delivery, referred to as artificial pancreas (AP), will ideally eliminate the need for user inputs. Several control algorithms for AP have been proposed, such as model predictive control (MPC), 5-10 proportional-integral-derivative (PID) control, and fuzzy logic control. 15,16 Limitations of current insulin therapy mean that novel delivery regimens to obtain optimal postprandial BG control that can compensate for intervarietal differences in meal absorption rates are needed Following early efforts in mixed meal modeling, 21 compilations of different absorption patterns for meals with varying fat content were developed to cover wide disparities in insulin compensation requirements. 22,23 Although combining 1 Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA 2 Sansum Diabetes Research Institute, Santa Barbara, CA, USA Corresponding Author: Francis J. Doyle III, PhD, Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA , USA. doyle@engineering.ucsb.edu

2 958 Journal of Diabetes Science and Technology 8(5) fat content. Four-hour dual and square waves perform significantly better in avoiding hypoglycemia, but still fall short of the optimal basal bolus scheme, discussed in the present work, in minimizing total BG excursion beyond the target of 110 mg/dl. Traditional basal bolus and closed-loop AP therapies with user announcements were studied in the present work. Novel insulin delivery profiles were identified through in silico trials for multiple meal compositions using particle swarm optimization (PSO). 26 Figure 1. Simulated blood glucose trajectories and insulin profile comparison between a novel optimized insulin regimen under closed-loop control and optimized proportional-integralderivative controller as referenced in the fifth section of this article, normal single bolus, dual wave (50% of the full bolus given initially, followed by 50% given as a remainder), and square wave regimens following a 100 g CHO high-fat pasta meal for 1 virtual subject. The green shaded region represents the near-euglycemic zone, and the yellow region represents the zone between hypo- and hyperglycemic thresholds. The insulin profile subplot has been zoomed to facilitate view. such a meal library with a controller within the loop were explored, 23 meal compensation beyond basal bolus therapies has been limited. Insulin advisory software, 4,24 called bolus wizards, 25 were tested under clinical conditions, but these merely facilitate the derivation of bolus amounts and still fundamentally depend on impulse deliveries. Current insulin delivery profiles are limited to single boluses (instantaneous insulin dose) and/or dual waves (instantaneous dose with a prolonged wave-like delivery). Single boluses work well for fast absorbing meals, but are not optimal for slower absorbing high-fat meals due to increases in risk of early hypoglycemia. While some studies suggest dual wave insulin delivery improves BG control following slow absorbing meals, 1 optimal insulin delivery regimens for these meals have not been verified. Figure 1 compares the simulated representative performances of various insulin regimens following a high-fat meal to illustrate the need of better control protocols. As can be seen in Figure 1, the single bolus strategy causes a significant hypoglycemic event for meals with high Simulation of Meal Profiles The present work was performed using the University of Virginia/Padova (UVA/Padova) metabolic simulator. 27,28 This simulator reproduces the variations in insulin action, blood glucose dynamics, and meal absorption parameters seen in the general population, and allows for testing of a variety of scenarios utilizing subcutaneous insulin delivery using CSII pumps and sensing of BG with continuous glucose monitors (CGMs). This study utilizes 10 in silico adult subjects included in the distributed version of the simulator for investigational purposes. Preliminary investigations using the given simulator have been accepted by the FDA in lieu of animal trials prior to multiple clinical trials. An auxiliary meal delivery rate was introduced to the simulator to enable simulation of slow absorbing high-fat meals. The auxiliary meal delivery rate was tuned to qualitatively replicate postprandial blood glucose profiles in literature. Simulated profiles for the 2 high-fat meals studied were generated under similar conditions as the published data, considering the time of the postprandial peak as the criterion for a good match. The mean blood glucose profiles of 10 subjects were compared with published data from Jones et al 29 and Normand et al. 17 Jones et al 29 investigated 26 adults with T1DM to determine the optimal insulin regimen for a pizza meal. The subjects consumed 3 pizza slices with approximately 90 g of CHO and 42 g of fat. Insulin was delivered as a bolus, a 4- or 8-hour dual wave. Normand et al 17 investigated 9 healthy women to determine the influence of dietary fat on postprandial glucose metabolism. One meal consisting 75 g of pasta with a fat content of 55% was chosen from this study for in silico evaluation. Each reported scenario was simulated under subject specific optimal basal bolus (open loop) insulin therapy within the UVA/Padova simulator. The meal delivery rates were optimized based on least squares difference between simulated and literature reported time and value of the postprandial peak given meals with reported CHO and fat content for each scenario. The resulting optimized meal delivery rates are shown in Figure 2. The modified simulator with optimized meal delivery rates qualitatively replicate published clinical data. Figure 3 shows that altering the meal delivery rate made possible the replication of the time to postprandial peak for both mediumfat pizza meals and high-fat pasta meals. Although there is a

3 Srinivasan et al 959 Figure 2. Ten subject average glucose absorption profiles for 3 different meal types, each containing 50 g of CHO. qualitative mismatch in the magnitude of the glucose excursion for the high-fat pasta meal, the time of the peak for both meal types conform to published data and is of greater interest for insulin regimen optimization as this can determine the optimal timing of the insulin deliveries. Global Optimization Approach Novel insulin delivery profiles are needed to improve postprandial BG control and provide appropriate bolus recommendations for a wide variety of meals. Delivery options are currently limited to normal, dual wave, and square wave boluses. As meal absorption rates are influenced by its composition, insulin regimens must be altered accordingly for optimal control. Novel delivery profiles for different meals were formulated as an optimization problem. The problem was designed as a multiple delivery scheme with 3 optimization variables for each insulin delivery: the time of delivery, the delivery duration, and the fraction of the full dose. The regimen s performance was characterized by the cost function in Equation 1. t e and t h are time in neareuglycemia ( mg/dl) and hypoglycemia (below 70 mg/dl), respectively. t s represents total simulation time and G i denotes ith recorded average BG concentration. N represents the number of sample points in simulated response (12 data points per hour, 12 hours for a total value of 144), chosen to normalize the summed square of deviations of blood glucose from the set point to an order 1. t j W t 2 N s h 1 ( Gi SP) = + + (1) te ts N i SP The cost function is designed to maximize time in euglycemia, minimize time in hypoglycemia, and reduce deviations from the baseline SP of 110 mg/dl, each scaled to be unitless and of order 1. Hypoglycemia can have life-threatening Figure 3. (A) Comparison of simulated 10 subject average blood glucose responses to a 90 g CHO pizza meal and published data from Jones et al 29 given a full insulin bolus at the time of the meal. (B) Comparison of simulated 10 subject average blood glucose response profiles for a 63.4 g CHO high-fat pasta meal and a simulated reference profile based on in silico data from Herrero et al. 22 The dashed lines represent min-max profiles, and the solid line at 110 represents the blood glucose concentration at the start of meal. The scenarios were simulated under basal insulin therapy only. short-term consequences, 2 and was weighted 5 times the other terms (ie, W = 5 ). A PSO algorithm was implemented to find optimal open- and closed-loop insulin profiles. It is a population-based algorithm in which the positions of a set of potential solutions (particles), each representing a point in the parameter space, are evaluated and improved iteratively by the given cost function. 26 Several reports have tested the performance of the PSO algorithm against genetic algorithm (GA), another widely used heuristic search method that is similarly population-based with simulated information sharing. Results show that while the quality of solutions reached by either algorithm for those problems explored were similar, computational efficiency of the PSO is as much as 6-fold greater than the GA. Up to 4 insulin delivery waves were evaluated based on 3 parameters each the beginning of the wave (m t -0.5 < t s < m t + 5), the length of the wave (0 < t L < 3), and the size of the wave (0 < I w < 1), where m t represents time of the meal. The time based parameters are expressed in hours, whereas I w is unitless and denotes the wave size in terms of a fraction of the full dose. The total insulin delivery was constrained to be no greater than the quantity calculated by each subject s insulin to CHO (I:C)

4 960 Journal of Diabetes Science and Technology 8(5) ratio and meal size. A total of 72 particles were utilized to sufficiently cover the parameter space, and each particle was moved through the search space ( Xi, Vi, PL, Pg R 16 ) by 4 vectors as shown in Equations 2 to 5. Xi ts1i tl1i Iw1i ts2i... Iw4i (2) = [ ] = [ 1 1 V ] = [ ] Vi Vs i VL i w i Vs i... Vw i (3) PL ts L tl L Iw L ts L... Iw L (4) Pg ts1g tl1g Iw1g ts2g... Iw4g (5) = [ ] X i represents current position of the particle in parameter space, V i is the current velocity of the particle in each dimension, P L is the locally best found position, and P g is the globally best found position. The position of each particle was then updated according to Equations 6 and 7, Vi t+ 1 = SFVi t + Cor1( Pi t Xi t )+ Sor2 ( Pg t Xi t ) (6) X + 1 = X + V + 1 (7) i t i t i t where S F is 0.9, a scaling factor of particle inertia, C o (0.5) and S o (1.25) are cognitive and social coefficients, and parameters r 1 and r 2 are random numbers in the interval (0,1). 26 The cost of each particle was evaluated at each iteration according to Equation 1. The aim of the algorithm was to progressively move the 72-particle population toward the optimal solution for each scenario. During each iteration of the algorithm, the cost function for each particle was evaluated, and the best parameter combination was recorded. The algorithm was formulated to stop if the improvement of the cost function evaluation of the current best point from the previous iteration s best point, or fitness function tolerance, was less than 10E-8 for more than 10 generations, or if a maximum of 120 iterations was reached. The PSO algorithm was implemented in this manner to find the best individualized/generalized insulin delivery regimens for meals of different CHO and fat content during open and closed loop. Prior to the identification of delivery regimens under closed loop, tunable parameters for the simple controller utilized during the closed loop were also identified based on these settings. Optimized Basal Bolus Regimens General optimal insulin regimens (GORs) for 10 in silico subjects were found using PSO for 9 different scenarios. A total meal CHO of 50, 75, or 100 g and low, medium, or high fat content was specified for each scenario. These scenarios were designed to cover the range of variability in meal content seen in the daily life. In the context of this study, a GOR is a recommended set of insulin deliveries based on any subject s I:C ratio for instance, the insulin regimen for typical meal compensation can be described as a GOR where a bolus amounting to 100% of the quantity as calculated by the I:C is given at the time of meal. Three different meal types with varying absorption rates were considered for the optimization, and each type was simulated with 50, 75, and 100 g carbohydrate content. For each meal scenario, a GOR was acquired through a combined optimization for 10 in silico subjects. Similarly, individual optimal regimens (IORs) were also determined for each scenario. They are, unlike GORs, individually tailored regimens obtained through separate optimizations for each of the 10 subjects, utilized to compare the validity of each GOR. A summary of the GOR results is presented in Figure 4. Figure 4 shows that the optimal insulin delivery profile for low-fat meals with 50 and 75 g of CHO is a normal bolus administered 30 minutes prior to the meal, whereas the optimal profile for 100 g low-fat meals is a 15-minute square wave delivered starting at the same time. This is feasible considering the increased risk of hypoglycemia that follows normal bolus compensation for larger meals. The novel regimens maintain most subjects within the safe BG range of mg/dl. The scheduling of preprandial insulin deliveries is influenced by the constraint for the earliest dose, set to be 30 minutes before the meal in consideration of the practical difficulties of meal planning. The fast digestion of low-fat meals causes rapid glucose absorption that is faster than insulin absorption and action given subcutaneous delivery and thus needs preprandial insulin to avoid severe hyperglycemia. In contrast, the GOR for medium-fat pizza meals with 50 g CHO is a 2-hour square wave, and the optimal profiles for 75 and 100 g CHO meals are biphasic with the insulin still delivered within a 2-hour postprandial period. The regimens maintain the BG within mg/dl for most subjects. Since medium-fat pizza meals exhibit slow glucose absorption due to the longer digestion process, 20 the optimized regimens do not include preprandial insulin (see Figure 4). Similarly, the optimal profiles for 50, 75, and 100 g CHO high-fat pasta meals are biphasic, multiphasic, and multiphasic over 4 hours, respectively. Increasing number of waves with meal size is realistic since a greater, steady glucose excursion would require multiple frequent insulin deliveries to avoid hyperglycemia. The novel regimens maintain all but 1 subject within mg/dl. A summary of the novel basal bolus regimens can be found in Table 1. Large meals and interpatient variations present great challenges in BG control and contribute to the difficulty of prescribing general recommendations. Hence, IORs were next determined to confirm the general regimens, and to find potential trends that may be useful in prescribing regimens for certain groups of patients. The IORs and GORs for 100 g low-fat, high-fat pizza, and high-fat pasta meals are presented in Figure 5. Figure 5 shows that highly insulin sensitive subjects (high I:C ratios) display a consistent trend of short wave patterns,

5 Srinivasan et al 961 Figure 4. Summary of the performance of general optimal insulin regimens (GORs) for 3 different meal types of various sizes. The figure shows the blood glucose response profiles and insulin delivery patterns for 10 in silico subjects given 9 different meal scenarios. The green shaded region represents the near-euglycemic zone, and the yellow region represents the zone between hypoand hyperglycemic thresholds. Table 1. Novel GORs for Meals Comprising 50, 75, and 100 g of CHO. Meal type Low fat High-fat pizza High-fat pasta Meal size (g) Wave I % of insulin dose Starting time (min) Duration (min) Wave II % of insulin dose Starting time (min) Duration (min) Wave III % of insulin dose Starting time (min) Duration (min) Wave IV % of insulin dose 4.5 Starting time (min) +210 Duration (min) 0 whereas the less sensitive subjects benefit from extended waves. Figure 6, showing the IORs of in silico subjects for a high-fat pizza meal, grouped by their insulin sensitivities, also qualitatively demonstrates this trend, suggesting that patients with low insulin sensitivity require a longer delivery period due to their relatively slow insulin action.

6 962 Journal of Diabetes Science and Technology 8(5) deliveries, biphasic pattern with varying time of deliveries, and multiphasic patterns. Extremely sensitive subjects display the most consistent trend and receive optimal control from the first trend type. The GOR is similar to the average individual profile despite significant variations between the individual regimens. Furthermore, statistical tests show insignificant difference in performance between the regimens. Similarly, the IORs for the high-fat pasta meals display bi- and multiphasic patterns. IORs of highly sensitive subjects are biphasic, whereas those of less sensitive subjects are multiphasic. This is reasonable since multiple waves can cause increased fluctuations in BG for sensitive subjects. The GOR can maintain all but 1 subject within the safe BG range, similar to the IORs, showing the relevance and applicability of a GOR. Figure 5. Comparison of individual optimal regimens (IORs), the average individual profile, and the general optimal insulin regimen (GOR) for 10 in silico subjects when given 100 g CHO meals of different fat content. Overall, IOR of most subjects for the low-fat meals is a short wave, validating the GOR. Similarities between the GOR and the average individual profile indicate providing a general recommendation to patients is a reasonable approach for this meal type. This was also confirmed by statistical paired t tests with an alpha level of.05, revealing no significant difference in performance between the optimized general and individual regimens. A comparison of the average performance of the GORs and IORs for a 100 g meal with different fat contents can be found in Table 2. The results for the high-fat pizza meal indicate notable variations between the individual regimens, mainly determined by insulin sensitivity. Three distinguishable trends can be observed: biphasic pattern with specific time of Optimized Closed-Loop Regimens An AP with premeal boluses can benefit from combining controller action with a fixed supplementary insulin regimen specific to each meal. A controller regulates insulin infusion based on feedback of calculated error between the measured and desired BG. A PID controller calculates control action based on current error, summation of past errors, and rate of change of current error. The tuning of 3 parameters that define a simple, fixed parameter PID controller (K c, τ I, and τ D ) was optimized to minimize the cost function as in Equation 1 simultaneously for 10 virtual subjects within the UVA/Padova simulator when given a meal with 50 g of fast-absorbing CHO under closed-loop control. A PSO algorithm using the same settings as in section III was utilized to find the optimal values. Optimization of GORs of 9 different meal scenarios was performed with PID control, using CGM values as its input. A summary of results is shown in Figure 7. Optimized low-fat closed-loop regimens presented in Figure 7 are nearly identical to results obtained in basal bolus setting. The proposed high-fat pizza meal GORs are biphasic with a 2-hour postprandial insulin infusion compared to the basal bolus regimen, which consists of 1 long wave. This difference can be attributed to limited control action due to slow glucose excursion, explaining the initial short wave in the closed-loop regimen for the 50 g meal to address the need for fast insulin infusion. Likewise, the dissimilarity for 100 g meals can be attributed to increased initial derivative control action as a result of the fast glucose excursion that follows large meals. Therefore, the closed-loop regimen for this meal is initialized by slower insulin infusion than the smaller meals. The novel closed-loop regimens maintain all subjects within mg/dl, even for the largest meal size. A statistical comparison to the basal bolus regimens shows significant improvement in performance of the closed-loop approach.

7 Srinivasan et al 963 Figure 6. Observed trends in individually optimized regimens for 10 in silico subjects in the case of high-fat pizza meals. The left plot shows the group of in silico subjects with the highest insulin sensitivities and whose individual optimal regimens (IORs) are biphasic. The middle plot presents another group of subjects that have biphasic insulin delivery patterns, and the right plot shows the subjects whose insulin regimens are multiphasic. Table 2. Comparison of the Mean Performances of the GOR and IOR for Meals With 100 g CHO and Varying Fat Content. Metric Low fat High-fat pizza High-fat pasta Regimen type GOR IOR GOR IOR GOR IOR Deviation from 110 (mg/dl) % time within mg/dl % time within mg/dl Post prandial peak (mg/dl) GOR, general optimal insulin regimen; IOR, individual optimal regimen. The PSO algorithm was also used to determine the optimal closed-loop GORs for high-fat pasta meals. The 50 and 75 g meal regimens are multiphasic, whereas the 100 g meal regimen is biphasic with insulin being infused over a 4-hour postprandial period. This can be attributed to the faster rise in BG concentration caused by large meals, resulting in higher derivative action and reducing the need for frequent insulin waves. The optimized regimens for high-fat pasta meals maintain all subjects well within the safe BG range. A summary of the regimen designs can be found in Table 3. These promising results indicate that controller action in combination with GORs can provide very effective control of postprandial glucose excursions. Discussion The insulin regimen for a standard meal in conventional basal bolus therapy is a normal bolus, 33 and the performances of our novel open- and closed-loop regimens were compared to this scheme in Figure 8, showing that the novel regimens perform significantly better in terms of the postprandial peak, time in euglycemia, and deviations from the baseline concentration for all meal scenarios. The normal bolus performs adequately for low-fat meals, but is not optimal for slower absorbing meals. This confirms published data from recent clinical trials, 29,34,35 which suggest dual wave insulin delivery as optimal for high-fat meals. Traditional normal bolus and square wave boluses have also been considered for such meals. However, these regimens have not been as successful at attenuating the postprandial BG peak as the dual wave. 34 The results obtained in this study also show that square waves, biphasic, and multiphasic regimens better attenuate postprandial glucose excursions following high-fat meals. Although the dual wave bolus is currently considered optimal for high-fat meals, novel open- and closed-loop GORs generated in this study show superior postprandial control in in silico trials. In addition, further investigations of GORs were conducted to test for wider applicability to patients beyond the

8 964 Journal of Diabetes Science and Technology 8(5) Figure 7. Summary of closed-loop general optimal insulin regimens (GORs) for 3 different meal types of various sizes. The figure shows the blood glucose response profiles and insulin delivery patterns for 10 in silico subjects given 9 different meal scenarios. The green shaded region represents the near-euglycemic zone, and the yellow region represents the zone between hypo- and hyperglycemic thresholds. Table 3. Novel General Optimal Insulin Regimens in a Closed-Loop Setting for Meals Comprising 50, 75, and 100 g of Carbohydrates. Meal type High-fat pizza High-fat pasta Meal size g Wave I % of insulin dose Starting time (min) Duration (min) Wave II % of insulin dose Starting time (min) Duration (min) Wave III % of insulin dose Starting time (min) Duration (min) training population. The full UVA/Padova simulator allows simulation of 100 in silico subjects that thoroughly cover interindividual variability in insulin-glucose dynamics. Figure 9 shows performances of the 6 optimized open- and closed-loop GORs for meals with varied fat content for this larger population, which validate the improvements in blood glucose control using the proposed scheme in the 100 subject testing population.

9 Srinivasan et al 965 Figure 8. Comparison of insulin regimen performance for 3 different meal types, each comprising 100 g of CHOs. The solid curves represent the average blood glucose response profiles for 10 in silico subjects, and the area between the dashed lines represents the minmax profiles. The green shaded region represents the near-euglycemic zone, and the yellow region represents the zone between hypo- and hyperglycemic thresholds. Finally, the results of this study are more robust to uncertainties in meal size and insulin-to-cho ratio estimates. Tables 4 to 6 show the effect of 25% over- and underestimations of 2 parameters that effect insulin delivery to compensate meals meal size estimate and I:C ratio estimate on each bolus delivery regimens and for low, medium, and high-fat 100 g CHO meals. Overall results from this analysis show more robustness of the novel closed-loop schemes versus existing schemes. The data also indicate that closed-loop regimens combining a PID controller with a supplementary GOR have smaller variation in performance over the different scenarios. The proposed scheme in this study does not rely on optimal basal therapy and is thus a realistic strategy with significant potential real-life applications in AP. A clinical trial of the GOR is necessary to confirm results before practical applications of the proposed regimens. Conclusion Qualitative replications of published data of high-fat meal absorption were conducted in silico, and a library of novel meal compensation strategies for a variety of meal compositions was constructed using PSO methodology. Optimization yielded novel open- and closed-loop insulin regimens that provide better control of postprandial glucose excursions than existing schemes. Novel delivery patterns propose unique waveforms not available in existing insulin pump wizards. GORs for low-fat meal are a normal bolus or a short square wave delivered at least 30 minutes prior to the meal. GORs for high-fat meals are typically biphasic, but can extend to multiple phases depending on meal composition. Preliminary investigations of the GORs under varied fat content also display bi- or multiphasic patterns. Closed-loop schemes with optimized supplementary delivery profiles are significantly more robust to uncertainties compared to traditional schemes despite wide variations in individual subject insulin sensitivities. Since the proposed schemes do not rely on individual optimizations, it is a more realistic strategy with significant potential for practical applications in an AP.

10 966 Journal of Diabetes Science and Technology 8(5) Figure 9. Summary of open- and closed-loop general optimal insulin regimen (GOR) performance under the validation scenario for 3 meal types with different fat content and 100 g CHO, under the 100 in silico subjects for the UVA/Padova simulator. The figure shows the blood glucose response profiles for 100 in silico subjects in the full version of the UVA/Padova simulator given 3 different meal scenarios. The green shaded region represents the near-euglycemic zone, and the yellow region represents the zone between hypo- and hyperglycemic thresholds. Table 4. Robustness Analysis Results for a Normal Bolus and 2 Novel Insulin Regimens Given a Low-Fat Meal Comprising 100 g of CHO. Meal size estimate I:C ratio estimate Regimen 25% Nominal +25% 25% Nominal +25% Normal bolus % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal open loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal closed loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl)

11 Srinivasan et al 967 Table 5. Robustness Analysis Results for a Normal Bolus and 2 Novel Insulin Regimens Given a High-Fat Pizza Meal Comprising 100 g of CHO. Meal size estimate I:C ratio estimate Regimen 25% Nominal +25% 25% Nominal +25% Normal bolus % time in hyperglycemia 6, , % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal open loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal closed loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Table 6. Robustness Analysis Results for a Normal Bolus and 2 Novel Insulin Regimens Given a High-Fat Pasta Meal Comprising 100 g of CHO. Meal size estimate I:C ratio estimate Regimen 25% Nominal +25% 25% Nominal +25% Normal bolus % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal open loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Optimal closed loop % time in hyperglycemia % time in hypoglycemia Peak blood glucose (mg/dl) Normalized AUC (mg/dl) Abbreviations AP, artificial pancreas; BG, blood glucose; CGM, continuous glucose monitor; CHO, carbohydrate; CSII, continuous subcutaneous insulin injection; GA, genetic algorithm; GOR, general optimal insulin regimen; IOR, individual optimal regimen; MPC, model predictive control; NIH, National Institutes of Health; PID, proportional-integral-derivative; PSO, particle swarm optimization; T1DM, type 1 diabetes mellitus; UVA/Padova, University of Virginia/Padova. Acknowledgments The full population UVA/Padova simulator was received from Dr Claudio Cobelli and Dr Boris Kovatchev for research purposes. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

12 968 Journal of Diabetes Science and Technology 8(5) Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health grant DP3DK References 1. Daneman D. Type 1 diabetes. Lancet. 2006;367: Stemman M. Predictive control of diabetic glycemia. Lund, Sweden: Lund University; Farmer TG Jr, Edgar TF, Peppas NA. The future of open- and closed-loop insulin delivery systems. J Pharm Pharmacol. 2008;60: Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. Diabetes Technol Ther. 2010;12: Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a personalized artificial pancreas. Diabetes Care. 2013;36: Hovorka R, Kumareswaran K, Harris J. Overnight closed-loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomized controlled studies. BMJ. 2011; Parker RS, Doyle FJ III, Peppas NA. A model-based algorithm for blood glucose control in type 1 diabetic patients. IEEE Trans Biomed Eng. 1999;46: Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010;4: Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375: Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25: Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31: Steil GM, Palerm C, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab. 2011;96: Wintergerst KA, Buckingham B, Deiss D, et al. Glucose control in pediatric intensive care unit (PICU) patients using an insulin-glucose algorithm. Diabetes. 2006;55:A103-A Lee JB, Dassau E, Seborg DE, Doyle FJ III. Model-based personalization scheme of an artificial pancreas for type 1 diabetes applications. Proc Amer Contr Conf. 2013; Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care. 2010;33: Grant P. A new approach to diabetic control: fuzzy logic and insulin pump technology. Med Eng Phys. 2007;29: Normand S, Khalfallah Y, Louche-Pelissier C, et al. Influence of dietary fat on postprandial glucose metabolism (exogenous and endogenous) using intrinsically (13)C-enriched durum wheat. Br J Nutr. 2001;86: Galgani J, Aguirre C, Diaz E. Acute effect of meal glycemic index and glycemic load on blood glucose and insulin responses in humans. Nutr J. 2006;5: Freckmann G, Kalatz B, Pfeiffer B, Hoss U, Haug C. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2):S347-S Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14: Roy A, Parker RS. Mixed meal modeling and disturbance rejection in type I diabetic patients. Conf Proc IEEE Eng Med Biol Soc. 2006;1: Herrero P, Palerm CC, Dassau E, et al. A glucose absorption model library of mixed meals for in silico evaluation of artificial β-cell control algorithms. J Diabetes Sci Technol. 2008;2:A Dassau E, Herrero P, Zisser H, et al. Implications of meal library & meal detection to glycemic control of type 1 diabetes mellitus through MPC control. Paper presented at: 17th IFAC World Congress; 2008; Seoul, Korea. 24. Rossetti P, Ampudia-Blasco FJ, Laguna A, et al. Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing-the ibolus-in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial. Diabetes Technol Ther. 2012;14: Perrenoud L, Dirlewanger M, Bussien C, et al. Curriculum for use of the bolus wizard for diabetic children and adolescents carrying an insulin pump and their parent (paradigm 522 or 722, 554 or 754 Medtronic (R) and Accu-Check (R) Aviva Combo, Roche). Diabetes Metab. 2012;38:A126-A Kennedy J, Eberhart R. Particle swarm optimization IEEE Int Conference Neural Netw Proc. 1995;1-6: Dalla Man C, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007;54: Kovatchev BP, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009;3: Jones SM, Quarry JL, Caldwell-McMillan M, Mauger DT, Gabbay RA. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther. 2005;7: Hassan R, Cohanim B, de Weck OL, Venter G. A comparison of particle swarm optimization and the genetic algorithm. Paper presented at: 1st AIAA Multidisciplinary Design Optimization Specialist Conference; April 2005; Austin, TX. 31. Boeringer DW, Werner DH. Particle swarm optimization versus genetic algorithms for phased array synthesis. IEEE Trans Antenn Propag. 2004;52: Panda S, Padhy NP. Comparison of particle swarm optimization and genetic algorithm for FACTS-based controller design. Appl Soft Comput. 2008;8: Kordonouri O, Hartmann R, Remus K, et al. Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapy. Pediatr Diabetes. 2012;13: Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med. 2002;19: Scaramuzza AE, Iafusco D, Giani E, et al. The optimal type of bolus following a pizza meal in children and adolescents with type I diabetes. Diabetologia. 2008;51:S381-S382.

An Improved PID Switching Control Strategy for Type 1 Diabetes

An Improved PID Switching Control Strategy for Type 1 Diabetes An Improved PID Switching Control Strategy for Type 1 Diabetes Gianni Marchetti, Massimiliano Barolo, Lois Jovanovic, Howard Zisser, and Dale E. Seborg, Member, IEEE Department of Chemical Engineering

More information

Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control

Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control Proceedings of the 17th World Congress The International Federation of Automatic Control Seoul, Korea, July 6-11, 28 Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes

More information

Insulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake

Insulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake Remei Calm 1, Maira García-Jaramillo 1, Jorge Bondia 2, Josep Vehí 1 1

More information

Type 1 Diabetes - How the HHM System Evaluates Its Performance

Type 1 Diabetes - How the HHM System Evaluates Its Performance 511730DSTXXX10.1177/1932296813511730Journal of Diabetes Science and TechnologyFinan et al research-article2014 Original Article Closed-Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer

More information

Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices

Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices Authors: Ayan Banerjee Impact Lab, Arizona State University abanerj3@asu.edu Yi Zhang Center for Devices and Radiological Health,

More information

Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD

Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD Carbohydrate to Insulin Ratio, circa 1935 Standard Insulin Replacement Regimen

More information

Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric

Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric Paper No. 243a Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric Cesar C. Palerm, Howard Zisser, Wendy C. Bevier,

More information

Abstract SYMPOSIUM. Journal of Diabetes Science and Technology

Abstract SYMPOSIUM. Journal of Diabetes Science and Technology Journal of Diabetes Science and Technology Volume 3, Issue 5, September 2009 Diabetes Technology Society SYMPOSIUM Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery

More information

A Fuzzy Controller for Blood Glucose-Insulin System

A Fuzzy Controller for Blood Glucose-Insulin System Journal of Signal and Information Processing, 213, 4, 111-117 http://dx.doi.org/1.4236/jsip.213.4215 Published Online May 213 (http://www.scirp.org/journal/jsip) 111 Ahmed Y. Ben Sasi 1, Mahmud A. Elmalki

More information

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden: tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric

More information

Numerous studies have demonstrated that utilization

Numerous studies have demonstrated that utilization DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Supplement 2, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2015.0369 ORIGINAL ARTICLE Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among

More information

[Frida Svendsen and Jennifer Southern] University of Oxford. October 2014

[Frida Svendsen and Jennifer Southern] University of Oxford. October 2014 In adolescents with poorly controlled type 1 diabetes mellitus, could a bionic, bihormonal pancreas provide better blood glucose control than continuous subcutaneous insulin infusion therapy? [Frida Svendsen

More information

Diabetes Care 36:801 809, 2013

Diabetes Care 36:801 809, 2013 Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Clinical Evaluation of a Personalized Artificial Pancreas EYAL DASSAU, PHD 1,2,3 HOWARD ZISSER, MD 1,3 REBECCA A. HARVEY,

More information

Insulin Pump Therapy: What Is the Evidence for Using Different Types of Boluses for Coverage of Prandial Insulin Requirements? Abstract.

Insulin Pump Therapy: What Is the Evidence for Using Different Types of Boluses for Coverage of Prandial Insulin Requirements? Abstract. Journal of Diabetes Science and Technology Volume 3, Issue 6, November 2009 Diabetes Technology Society COMMENTARY Insulin Pump Therapy: What Is the Evidence for Using Different Types of Boluses for Coverage

More information

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;

More information

Present and Future of Insulin Therapy: Research Rationale for New Insulins

Present and Future of Insulin Therapy: Research Rationale for New Insulins Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents

More information

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system ISHP Spring CE Conference April 12, 2015 St. Luke s Medical Center Randi Lynn Griffiths, PharmD Clinical outpatient pharmacist Boise VA Medical Center Boise, Idaho Alternative method for delivering insulin

More information

Universita degli Studi di Padova Facolta di Ingegneria

Universita degli Studi di Padova Facolta di Ingegneria Universita degli Studi di Padova Facolta di Ingegneria Finito di scrivere il giorno September 5, 01 utilizzando L A TEX ε UNIVERSITÀ DEGLI STUDI DI PADOVA FACOLTÀ DI INGEGNERIA Dipartimento di Ingegneria

More information

Reference. United States. 1. Introduction

Reference. United States. 1. Introduction 572 F. Doyle et al. / Journal of Process Control 17 (2007) 571 594 and actuators with sufficient authority to influence the controlled variables. As always, plant understanding is key. Biological systems

More information

Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12

Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12 Continuous or Intermittent Monitoring of Glucose in Interstitial (10120) Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10,

More information

A run-to-run framework for prandial insulin dosing: handling real-life uncertainty

A run-to-run framework for prandial insulin dosing: handling real-life uncertainty INTERNATIONAL JOURNAL OF ROBUST AND NONLINEAR CONTROL Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 1.12/rnc.113 A run-to-run framework for prandial insulin dosing: handling

More information

Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus

Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed

More information

Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS

Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS Idit F Liberty MD, Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel Aviv

More information

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of

More information

Medical Policy Insulin Pumps

Medical Policy Insulin Pumps Medical Policy Insulin Pumps Document Number: 027 Authorization required Insulin Pumps & supplies Notification within 24 hours of service or next business day No Prior Authorization Not covered Pulsatile

More information

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,

More information

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate

More information

Closed loop insulin delivery systems

Closed loop insulin delivery systems : 170-174, 2009 Closed loop insulin delivery systems R. Hovorka 1 DB. Dunger 2 1 Principal Research Associate, Diabetes Modelling Group, Department of Paediatrics, University of Cambridge, Cambridge, UK.

More information

Self-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime.

Self-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime. International Simposium on Robotics and Automation 24 August 25-27, 24 Self-tuning Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime. D.U. Campos-Delgado Facultad de Ciencias

More information

Insulin Pump Therapy. Jen Block, MSN, RN, CDE Stanford University Department of Pediatric Endocrinology

Insulin Pump Therapy. Jen Block, MSN, RN, CDE Stanford University Department of Pediatric Endocrinology Insulin Pump Therapy Jen Block, MSN, RN, CDE Stanford University Department of Pediatric Endocrinology Disclosures Member of Clinical Advisory Panel for Tandem Work on a variety of clinical trials funded

More information

8/7/2015. Disclosure to Participants. Type 1 Diabetes and Physical Activity: Integrating Data. Successful T1 Diabetic Athletes

8/7/2015. Disclosure to Participants. Type 1 Diabetes and Physical Activity: Integrating Data. Successful T1 Diabetic Athletes 8/7/2015 Sheri R. Colberg PhD, FACSM Professor of Exercise Science Old Dominion University Norfolk, VA Disclosure to Participants Notice of Requirements For Successful Completion Please refer to learning

More information

Artificial Pancreas Using a Personalized Rule-Based Controller Achieves Overnight Normoglycemia in Patients with Type 1 Diabetes

Artificial Pancreas Using a Personalized Rule-Based Controller Achieves Overnight Normoglycemia in Patients with Type 1 Diabetes DIABETES TECHNOLOGY & THERAPEUTICS Volume 16, Number 3, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2013.0229 ORIGINAL ARTICLE Artificial Pancreas Using a Personalized Rule-Based Controller Achieves

More information

ARTICLE IN PRESS Biomedical Signal Processing and Control xxx (2012) xxx xxx

ARTICLE IN PRESS Biomedical Signal Processing and Control xxx (2012) xxx xxx Biomedical Signal Processing and Control xxx (2012) xxx xxx Contents lists available at SciVerse ScienceDirect Biomedical Signal Processing and Control journa l h omepage: www.elsevier.com/locate/bspc

More information

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by

More information

Starting patients on the V-Go Disposable Insulin Delivery Device

Starting patients on the V-Go Disposable Insulin Delivery Device Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate

More information

Glucose-Insulin System based on Minimal Model: a Realistic Approach

Glucose-Insulin System based on Minimal Model: a Realistic Approach 2015 17th UKSIM-AMSS International Conference on Modelling and Simulation Glucose-Insulin System based on Minimal Model: a Realistic Approach Adriana Aguilera González, Holger Voos Interdisciplinary Centre

More information

THE OTHER 50% OF TDD: PRANDIAL INSULIN. Alison Evert, MS, RD, CDE

THE OTHER 50% OF TDD: PRANDIAL INSULIN. Alison Evert, MS, RD, CDE THE OTHER 50% OF TDD: PRANDIAL INSULIN Alison Evert, MS, RD, CDE NUTRITION THERAPY & INSULIN REQUIRING DIABETES OBJECTIVES Participant will be able to: List two formulas or Rules used to determine the

More information

INSULIN PRODUCTS. Jack DeRuiter

INSULIN PRODUCTS. Jack DeRuiter INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list

More information

Calculating Insulin Dose

Calculating Insulin Dose Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This

More information

Emma Jenkins BSc, RD, CEDT Diabetes Specialist Dietitian Royal Bournemouth Hospital Dorset, UK. Pens & calculators at the ready?!...

Emma Jenkins BSc, RD, CEDT Diabetes Specialist Dietitian Royal Bournemouth Hospital Dorset, UK. Pens & calculators at the ready?!... Emma Jenkins BSc, RD, CEDT Diabetes Specialist Dietitian Royal Bournemouth Hospital Dorset, UK Pens & calculators at the ready?!... Robert, age 42. Type 1 diabetes for 26yrs. HbA1c 76mmols/mol 2 recent

More information

Intensifying Insulin In Type 2 Diabetes

Intensifying Insulin In Type 2 Diabetes Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant

More information

Intensive Insulin Therapy in Diabetes Management

Intensive Insulin Therapy in Diabetes Management Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition

More information

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,

More information

SYSTEMS AND INFORMATION ENGINEERING

SYSTEMS AND INFORMATION ENGINEERING DEPARTMENT OF SYSTEMS AND INFORMATION ENGINEERING SIEFALL 2015 Associate Systems and Information Engineering Professor Gregory J. Gerling has his finger on the pulse of interdisciplinary research, bridging

More information

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step

More information

MANAGING DIET ON AN INSULIN PUMP.

MANAGING DIET ON AN INSULIN PUMP. Patient Information MANAGING DIET ON AN INSULIN PUMP. Dietetic Department Therapy Services Shrewsbury and Telford NHS Trust 1 Food Bolusing on a pump (ADJUSTING YOUR INSULIN WITH YOUR DIET) Hopefully you

More information

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Solomon S. Steiner, Lutz Heinemann, Roderike Pohl, Frank Flacke, Andreas Pfützner, Patrick V. Simms, Marcus Hompesch. EASD September 18, 2007

Solomon S. Steiner, Lutz Heinemann, Roderike Pohl, Frank Flacke, Andreas Pfützner, Patrick V. Simms, Marcus Hompesch. EASD September 18, 2007 Pharmacokinetics and Pharmacodynamics of Insulin VIAject TM, Insulin Lispro and Regular Human Insulin When Injected Subcutaneously Immediately Before a Meal in Patients with Type 1 Diabetes. Solomon S.

More information

Clinical Validity of Insulin Bolus Calculators

Clinical Validity of Insulin Bolus Calculators Clinical Validity of Insulin Bolus Calculators Howard A. Wolpert, MD Senior Physician, Joslin Diabetes Center Associate Professor, Harvard Medical School Director, Joslin Institute for Technology Translation

More information

A toolbox to improve algorithms for insulin-dosing decision support

A toolbox to improve algorithms for insulin-dosing decision support 548 A toolbox to improve algorithms for insulin-dosing decision support K. Donsa 1 ; P. Beck 1 ; J. Plank 2 ; L. Schaupp 2 ; J. K. Mader 2 ; T. Truskaller 1 ; B. Tschapeller 1 ; B. Höll 1 ; S. Spat 1 ;

More information

Continuous Subcutaneous Insulin Infusion (CSII)

Continuous Subcutaneous Insulin Infusion (CSII) IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus

More information

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY: Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Haidar A, Legault L, Matteau-Pelletier L, et

More information

Health Professional s. Guide to INSULIN PUMP THERAPY

Health Professional s. Guide to INSULIN PUMP THERAPY Health Professional s Guide to INSULIN PUMP THERAPY Table of Contents Introduction Presenting Insulin Pump Therapy to Your Patients When Your Patient Chooses the Pump Estimates for Starting Insulin Pump

More information

Issues in Emerging Health Technologies

Issues in Emerging Health Technologies Issues in Emerging Health Technologies Subcutaneous Open-loop Insulin Delivery for Type 1 Diabetes: Paradigm Real-Time System Issue 105 October 2007 Summary An open-loop insulin delivery system combines

More information

Insulin therapy and exercise

Insulin therapy and exercise DIABETES RESEARCH A ND CLINICAL PRACTICE 93S (2011) S73 S77 Insulin therapy and exercise Georgios I. Kourtoglou * St. Luke s General Hospital, Panorama, Thessaloniki, Greece ARTICLE INFO ABSTRACT Keywords:

More information

NONINSULIN-DEPENDENT diabetes mellitus

NONINSULIN-DEPENDENT diabetes mellitus 0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society An Overnight Insulin Infusion Algorithm Provides Morning

More information

Intensifying Insulin Therapy

Intensifying Insulin Therapy Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning

More information

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin

More information

Algorithms for Glycemic Management of Type 2 Diabetes

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors

The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors Howard A. Wolpert, MD 1 Diabetes is different to many other conditions Patient/Self Managed 2 To achieve the therapeutic goals

More information

Type 1 Diabetes - Managing a Critical Ratio

Type 1 Diabetes - Managing a Critical Ratio Objectives Students will learn about how ratios and proportions are a key part of managing Type 1 Diabetes Students will learn about the regulation of blood glucose through insulin (hormone) binding with

More information

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic

More information

Pump Therapy Indications:

Pump Therapy Indications: Insulin Pumping Getting Started March 7, 2008 Clinical Pearls To understand the rational behind pump therapy To explore patient preferences for and against insulin pump therapy Realistic expectations for

More information

Anomaly Detection in the Artificial Pancreas

Anomaly Detection in the Artificial Pancreas INGAR Instituto de Desarrollo y Diseño Consejo Nacional de Investigaciones Científicas y Técnicas Universidad Tecnológica Nacional Anomaly Detection in the Artificial Pancreas Luis Ávila, Ernesto Martínez

More information

Insulin Pump Therapy in children & Adolescents. Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist

Insulin Pump Therapy in children & Adolescents. Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist Insulin Pump Therapy in children & Adolescents Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist Insulin The most powerful agent we have to control glucose Banting and Best The Miracle

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of: Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus

More information

Type 1 Diabetes Management Based on Glucose Intake www.utmem.edu/endocrinology click Patients (Revised 7/13/2007)

Type 1 Diabetes Management Based on Glucose Intake www.utmem.edu/endocrinology click Patients (Revised 7/13/2007) Type 1 Diabetes Management Based on Glucose Intake www.utmem.edu/endocrinology click Patients (Revised 7/13/2007) The following is a system of insulin therapy, diet management, and blood glucose monitoring

More information

BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS

BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS CHAPTER 6: BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS WHAT IS BOLUS INSULIN? Bolus insulin dosages refer to the quick bursts of insulin given to cover the carbohydrates in meals or snacks

More information

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.

More information

Medical Nutrition Therapy for Diabetes

Medical Nutrition Therapy for Diabetes Medical Nutrition Therapy for Diabetes Marion J. Franz, MS, RD, CDE MarionFranz@aol.com Objectives: Discuss expected outcomes and when to evaluate effectiveness of MNT Review macronutrient questions Select

More information

The What, Why, Who & How of Insulin Pumps. Bridget Lydon May 2014

The What, Why, Who & How of Insulin Pumps. Bridget Lydon May 2014 The What, Why, Who & How of Insulin Pumps Bridget Lydon May 2014 Topics WHAT is an insulin pump HOW a pump works WHY use a pump WHO should use a pump Pharmac criteria for funded pumps All began back in

More information

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary

More information

Real-Time Improvement of Continuous Glucose Monitoring Accuracy

Real-Time Improvement of Continuous Glucose Monitoring Accuracy Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Real-Time Improvement of Continuous Glucose Monitoring Accuracy The smart sensor concept ANDREA FACCHINETTI, PHD 1

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

Gayle Curto, RN, BSN, CDE Clinical Coordinator

Gayle Curto, RN, BSN, CDE Clinical Coordinator Gayle Curto, RN, BSN, CDE Clinical Coordinator INTRODUCTION Historical Program Overview Leadership Team Mission Statement Diabetes Center Demographics for 2011 Older Adult Population HISTORICAL PROGRAM

More information

DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials

DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials Journal of Diabetes Science and Technology Volume 7, Issue 6, November 2013 Diabetes Technology Society SYMPOSIUM DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas

More information

The first injection of insulin was given on

The first injection of insulin was given on EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome

More information

School Nurse Role in Care and Management of the Child with Diabetes in Colorado Schools and Child Care Settings Position Statement 1 POSITION It is

School Nurse Role in Care and Management of the Child with Diabetes in Colorado Schools and Child Care Settings Position Statement 1 POSITION It is Schools and Child Care Settings Position Statement 1 POSITION It is the position of the Colorado Diabetes Resource Nurses that the school nurse is the only school staff member who has the skills, knowledge

More information

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding

More information

A Model-Based Approach to Synthesizing Insulin Infusion Pump Usage Parameters for Diabetic Patients

A Model-Based Approach to Synthesizing Insulin Infusion Pump Usage Parameters for Diabetic Patients A Model-Based Approach to Synthesizing Insulin Infusion Pump Usage Parameters for Diabetic Patients Sriram Sankaranarayanan, Christopher Miller, Rangarajan Raghunathan, Hadi Ravanbakhsh and Georgios Fainekos

More information

Optimization of PID parameters with an improved simplex PSO

Optimization of PID parameters with an improved simplex PSO Li et al. Journal of Inequalities and Applications (2015) 2015:325 DOI 10.1186/s13660-015-0785-2 R E S E A R C H Open Access Optimization of PID parameters with an improved simplex PSO Ji-min Li 1, Yeong-Cheng

More information

9/14/2015 DISCLOSURE. No Financial Conflicts of Interest to disclose. Neither the planners or presenter have any conflicts of interest to disclose.

9/14/2015 DISCLOSURE. No Financial Conflicts of Interest to disclose. Neither the planners or presenter have any conflicts of interest to disclose. Welcome to the COPE Webinar Series for Health Professionals! MacDonald Center for Obesity Prevention and Education (COPE) Goals September 16 2015 webinar Improve Your Practice Through the Application of

More information

Diabetes. New Trends Presented by Barbara Obst RN MS August 2008

Diabetes. New Trends Presented by Barbara Obst RN MS August 2008 Diabetes New Trends Presented by Barbara Obst RN MS August 2008 What is Diabetes Diabetes is a condition characterized by high levels of glucose. The glucose circulates in your blood and serves as the

More information

Health Policy Advisory Committee on Technology

Health Policy Advisory Committee on Technology Health Policy Advisory Committee on Technology Technology Brief Update Closed-loop Insulin Delivery System for the management of hypoglycaemia November 2012 State of Queensland (Queensland Health) 2012

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah

More information

4/7/2015 CONFLICT OF INTEREST DISCLOSURE OBJECTIVES. Conflicts of Interest None Heather Rush. Heather M. Rush, APRN, CDE Louisville, KY

4/7/2015 CONFLICT OF INTEREST DISCLOSURE OBJECTIVES. Conflicts of Interest None Heather Rush. Heather M. Rush, APRN, CDE Louisville, KY Heather M. Rush, APRN, CDE Louisville, KY CONFLICT OF INTEREST DISCLOSURE Conflicts of Interest None Heather Rush A conflict of interest exists when an individual is in a position to profit directly or

More information

CURRENT THERAPEUTIC RESEARCH

CURRENT THERAPEUTIC RESEARCH CURRENT THERAPEUTIC RESEARCH VOLUME 70, NUMBER I, FEBRUARY 2009 Case Series Adjusting the Basal Insulin Regimen of Patients With Type 1 Diabetes Mellitus Receiving Insulin Pump Therapy During the Ramadan

More information

Diabetes: When To Treat With Insulin and Treatment Goals

Diabetes: When To Treat With Insulin and Treatment Goals Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy

More information

Improving the Timing of Insulin Administration

Improving the Timing of Insulin Administration Lehigh Valley Health Network LVHN Scholarly Works Patient Care Services / Nursing Improving the Timing of Insulin Administration Jessica Buzinski BSN, RN Lehigh Valley Health Network Anna E. Dixon RN,

More information

The Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes

The Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes The Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes Ahmed Y. Ben Sasi College of Industrial Technology Misurata, Libya ahmed_bensasi@yahoo.co.uk Mahmud A. Elmalki

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Optimizing Insulin Therapy. Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors

Optimizing Insulin Therapy. Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors Optimizing Insulin Therapy Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors Introduction Diabetes management, and particularly self-management, has come a long way. Unfortunately,

More information

FDA Perspective on Closed-Loop Studies

FDA Perspective on Closed-Loop Studies FDA Perspective on Closed-Loop Studies Practical Ways to Achieve Targets in Diabetes Care July 19, 2014 Keystone, CO Courtney H. Lias, Ph.D. Office of In Vitro Diagnostic Device Evaluation and Safety Center

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information